Tivozanib (AV-951): Potent Pan-VEGFR Inhibitor for Precision Oncology

Executive Summary: Tivozanib (AV-951) is a second-generation, quinoline-urea tyrosine kinase inhibitor (TKI) with picomolar potency against VEGFR-2 (IC₅₀ = 160 pM), displaying minimal off-target kinase inhibition and robust antitumor activity in renal cell carcinoma (RCC) models (Schwartz 2022). Clinically, Tivozanib achieves a progression-free survival (PFS) of 12.7 months in metastatic RCC, outperforming earlier TKIs. It is highly soluble in DMSO (≥22.75 mg/mL), insoluble in water, and typically used at 10 μM for 48 hours in in vitro assays. Synergistic effects are observed when combined with EGFR inhibitors, enhancing apoptosis and growth inhibition in cellular models. Tivozanib’s selective inhibition of VEGFR signaling supports its utility in anti-angiogenic therapy workflows, with validated protocols for both preclinical and translational research (ApexBio).

Biological Rationale

Angiogenesis, the formation of new blood vessels, is required for tumor progression and metastasis. The vascular endothelial growth factor receptor (VEGFR) family—comprising VEGFR-1, VEGFR-2, and VEGFR-3—mediates angiogenic signaling in the tumor microenvironment. Pharmacological inhibition of VEGFRs disrupts tumor vascularization, limiting nutrient and oxygen supply to malignant cells (Schwartz 2022). Selective blockade of VEGFRs is a validated strategy in the treatment of solid tumors, particularly clear cell and papillary renal cell carcinoma. Tivozanib (AV-951) was developed as a next-generation pan-VEGFR inhibitor, aiming to maximize on-target effects and minimize off-target toxicities associated with first-generation TKIs. It targets the VEGFR pathway at multiple nodes, enabling comprehensive suppression of angiogenesis and tumor growth.

Mechanism of Action of Tivozanib (AV-951)

Tivozanib is a potent and selective inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3 tyrosine kinases. In biochemical assays, it exhibits an IC₅₀ of 160 pM against VEGFR-2. It is structurally defined as 1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea with a molecular weight of 454.86 Da (ApexBio). Tivozanib competitively binds to the ATP-binding site of VEGFRs, preventing receptor autophosphorylation and downstream signaling. In cellular models, Tivozanib inhibits VEGF-induced phosphorylation of VEGFRs and blocks proliferation and survival pathways in endothelial and tumor cells. It demonstrates low nanomolar inhibition of PDGFRβ and c-KIT. Off-target kinase inhibition is minimal, reducing the risk of systemic toxicity compared to sunitinib, sorafenib, and pazopanib. Tivozanib’s selectivity profile supports its use as a reference compound in studies of VEGFR signaling inhibition and anti-angiogenic therapy.

Evidence & Benchmarks

• Tivozanib inhibits VEGFR-2 with an IC₅₀ of 160 pM in cell-free kinase assays (Schwartz 2022, Table 2.1).
• It displays low nanomolar inhibition of PDGFRβ and c-KIT phosphorylation in cellular assays (Schwartz 2022, Fig. 3.2).
• In RCC xenograft models, Tivozanib produces significant tumor growth inhibition and vessel regression (Schwartz 2022, Ch. 5).
• Phase III clinical trials in metastatic RCC report a median PFS of 12.7 months for Tivozanib (1.5 mg orally, once daily for 3 weeks) (ApexBio).
• In vitro, 10 μM Tivozanib for 48 hours reliably inhibits VEGFR signaling and induces cell growth arrest (Schwartz 2022, Methods).
• Combination with EGFR inhibitors enhances apoptosis and cell viability reduction in ovarian carcinoma lines (Schwartz 2022, Ch. 6).

In contrast to existing reviews on Tivozanib’s in vitro functional assessments, this article provides updated quantitative benchmarks and clinical context for translational oncology. For a systems biology perspective and in-depth mechanistic modeling, see this resource, while our discussion here emphasizes validated workflow integration and comparable clinical outcomes.

Applications, Limits & Misconceptions

Tivozanib (AV-951) is used in preclinical and clinical oncology research to interrogate VEGFR-driven angiogenesis in solid tumors. It serves as a gold-standard pan-VEGFR inhibitor for benchmarking anti-angiogenic therapies and drug combinations. The compound’s favorable selectivity profile makes it suitable for in vitro, in vivo, and translational workflows. In RCC, Tivozanib is clinically approved and demonstrates competitive efficacy. Studies have reported synergistic effects with EGFR-directed therapies, particularly in ovarian carcinoma cell models. However, its efficacy is tumor-type and biomarker-dependent; not all VEGFR-expressing tumors respond equally.

Common Pitfalls or Misconceptions

• Tivozanib is not effective in VEGFR-independent tumors: Tumors lacking VEGFR pathway activation show poor response to Tivozanib.
• Solubility limitations: Tivozanib is insoluble in water and must be dissolved in DMSO or ethanol for experimental applications; improper solvent use can lead to precipitation and assay artifacts.
• Off-target safety: While off-target kinase inhibition is minimal, rare off-target effects may still occur at supra-physiological concentrations.
• Cell line variability: Dose-response and cytotoxicity may differ across cell lines due to inherent genetic and metabolic differences.
• Not a universal angiogenesis blocker: Tivozanib does not block non-VEGFR angiogenic pathways (e.g., FGF, Angiopoietin).

Workflow Integration & Parameters

Tivozanib is supplied as a solid, stable at -20°C, and should be freshly prepared for each experiment (ApexBio). It dissolves at ≥22.75 mg/mL in DMSO and ≥2.68 mg/mL in ethanol with gentle warming. For in vitro cell assays, use 10 μM for 48 hours unless otherwise specified. Avoid long-term storage of solutions to prevent degradation. For in vivo models, dosing protocols should be adapted according to species-specific pharmacokinetics.

For clinical research, Tivozanib is administered orally at 1.5 mg daily for 3 consecutive weeks, followed by a 1-week rest. Monitor for hypertension and proteinuria as class-related adverse events. When designing combination regimens with EGFR inhibitors, use validated synergy assays to confirm additive or synergistic effects (Schwartz 2022).

For guidance on integrating Tivozanib into advanced workflow systems, see this mechanistic analysis, which details translational applications and forward-looking strategies beyond standard protocols.

Conclusion & Outlook

Tivozanib (AV-951) is a highly potent, selective pan-VEGFR tyrosine kinase inhibitor with documented efficacy in preclinical models and clinical RCC trials. Its minimal off-target profile, robust anti-angiogenic activity, and workflow-friendly solubility parameters make it a reference standard for VEGFR signaling interrogation. As new combination strategies and biomarker-driven approaches emerge, Tivozanib’s role in precision anti-angiogenic therapy will likely expand. Researchers are advised to adhere to validated protocols, consider tumor-specific VEGFR dependence, and utilize proper solvent systems for optimal results. For further details, refer to the Tivozanib (AV-951) product page.